BCRF’s annual Symposium and Awards Luncheon will be held at the New York Hilton Midtown on Thursday, October 25. This highly-anticipated event honors BCRF-funded investigators—many of whom will be in attendance—for their devotion to ending breast cancer and their trailblazing scientific inquiry. At the Symposium, a panel of experts discuss topical issues across the fields of prevention, diagnosis, treatment and survivorship, and answer questions from the audience. This year’s symposium will explore “The Scientific Revolution in Early Breast Cancer”, moderated by Larry Norton, MD, Scientific Director of the BCRF Scientific Advisory Board.
Larry Norton, MD. Dr. Larry Norton, Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center is Professor of Medicine, Weill-Cornell Medical College. He is a founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation’s inception in 1993.
This year’s panelists are:
Judy Garber, MD, MPH. Dr. Garber is a medical oncologist and Director of the Center for Cancer Genetics and Prevention at the Susan Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, Director of the Cancer Risk and Prevention Clinic at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School, Boston, MA. Dr. Garber is the Chair of BCRF’s Scientific Advisory Board. Her research focuses on breast cancer genetics, including understanding familial risk with BRCA1, BRCA2, and PALB2 mutations, and prevention and risk reduction.
Hedvig Hricak, MD, PhD. Dr. Hricak is the recipient of BCRF’s 2018 Jill Rose Award for scientific excellence, to be awarded at the Luncheon following the Symposium. Dr. Hricak is a radiologist and a member of the Molecular Pharmacology & Chemist Program, Professor, Gerstner Sloan Kettering Graduate School, and Chairman of the Radiology Department at Memorial Sloan Kettering Cancer Center, New York, NY. Her research focuses on standardizing best practices in breast cancer imaging and interpretation and establishing an international network for training in breast cancer imaging and interpretation. The hallmark of her research career has been the validation of new imaging technologies and their translation into clinical practice, with a special emphasis on oncology.
Ben Ho Park, MD, PhD. Dr. Park is an oncologist and Professor of Oncology, Breast and Ovarian Cancer Program, and Associate Director, Hematology/Oncology Fellowship Program at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine in Baltimore, MD. His research focuses on the use of liquid biopsy, a non-invasive alternative to surgical biopsy, to monitor disease through treatment courses and assessment of tumor changes.
Joseph A. Sparano, MD. Dr. Sparano is a medical oncologist and Professor at the Albert Einstein College of Medicine, Vice-Chair, ECOG-ACRIN Cancer Research Group, Philadelphia, PA. His research focuses on the development and advancement of treatment for breast cancer, including new immunotherapy and collecting biospecimens to understand breast cancer response to specific therapies. Dr. Sparano led the landmark BCRF-supported TAILORx study that showed that women with early stage breast cancer can avoid chemotherapy.
For tickets and tables please call 646.497.2650.
Please remember BCRF in your will planning. Learn More
